ICON Acquires MolecularMD
ICON enhances it molecular diagnostic testing services, a key area in oncology research, with it's acquisition of MolecularMD.
ICON Reports Fourth Quarter and Full Year 2018 Results
Full year reported revenue was $2,595.8 million. Excluding the impact of ASC 606, full year revenue increased to $1,897.6 million from $1,758.4 million in 2017, an increase of 7.9%.
ICON Launches New Drug Safety Reporting Solution Ensuring Compliance Through Automation
Developed on platform deploying rule-based automation for timely delivery of drug safety information.
ICON UK Gender Pay Gap Report 2018
In accordance with The Equality Act 2010
ICON Issues Financial Guidance
For Full Year 2019
ICON wins Pharma Contract Services Company of the Year at the Pharma Industry Awards 2018
The Pharma Industry Awards recognise and celebrate innovative individuals and companies that demonstrate excellence in the Irish Pharma sector
ICON Reports Third Quarter 2018 Results
Q3 2018 Financial Results
ICON announces release of ADDPLAN® neo
Software provides an integrated technology platform for adaptive clinical trials
ICON Confirms Retirement of Co-Founder Dr. Ronan Lambe
After 28 years of Service
ICON Reports Second Quarter 2018 Results
Q2 2018 Financial Results